about
Sirtuins and Cancer: Role in the Epithelial-Mesenchymal TransitionFas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression.Lenalidomide in multiple myeloma: current experimental and clinical data.Antibody production and in vitro behavior of CD27-defined B-cell subsets: persistent hepatitis C virus infection changes the rules.Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?Para- and perirenal ultrasonographic fat thickness is associated with 24-hours mean diastolic blood pressure levels in overweight and obese subjectsEverolimus restrains the paracrine pro-osteoclast activity of breast cancer cells.Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations.The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis.Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18.Abdominal obesity is characterized by higher pulse pressure: possible role of free triiodothyronine.Myeloma bone disease: pathogenetic mechanisms and clinical assessment.Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications.Obesity as a major risk factor for cancer.Role of active drug transporters in refractory multiple myeloma.New insights into the molecular pathogenesis of langerhans cell histiocytosis.Immune Profile of Obese People and In Vitro Effects of Red Grape Polyphenols on Peripheral Blood Mononuclear Cells.Cell fusion and hyperactive osteoclastogenesis in multiple myeloma.Urokinase receptor (uPAR) ligand based recombinant toxins for human cancer therapy.Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy.Novel lenalidomide-based combinations for treatment of multiple myeloma.Cell fusion in myeloma marrow microenvironment: role in tumor progression.Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.Bone metastases in hepatocellular carcinoma: an emerging issue.The immune escape in melanoma: role of the impaired dendritic cell function.Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells.Erdheim-Chester disease: a systematic review.Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition.Avβ3 integrin: Pathogenetic role in osteotropic tumors.Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications.miRNAs in melanoma: a defined role in tumor progression and metastasis.Osteotropism of neuroendocrine tumors: role of the CXCL12/ CXCR4 pathway in promoting EMT in vitro.ALK gene alterations in cancer: biological aspects and therapeutic implications.NETs: organ-related epigenetic derangements and potential clinical applications.Mediterranean Diet and cancer risk: an open issue.An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation.A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progressionPTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression.Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe.In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells.
P50
Q26744502-F290C309-EEE9-4200-A121-32755167F428Q32061748-2E40A494-849F-4182-AE07-F407389A38C8Q34074803-E85B0010-623F-4014-A728-70F6851C9707Q34545880-37A5D440-3B85-4D5C-B43A-22C204DFD9D1Q35584599-9928AFCE-E92D-4A6B-ABC2-DCDBF537940DQ35792253-4E115739-AED5-4B07-A0FF-CB25A5D641F5Q35807838-607A033E-C5AA-4311-8A55-675F6F130E50Q35921190-42AC6537-6F69-460B-BB66-88D23097B499Q36242845-797C4783-8154-4A37-B777-99C019428C50Q36281248-25810010-F67A-4E91-AC9D-377E34D018BFQ36308226-96CB755E-792C-4412-8CBF-284C86413708Q36501851-AE07A6C7-40A4-4E1B-8AA0-763B3E83EF27Q36788273-0400C2FD-E3B5-4E88-899E-5B908291922EQ37171959-5C882D14-8918-4277-904C-7F31590516A8Q37387629-2533DA3E-055B-4D2F-8379-D7162DA0434EQ37589059-7795588F-4792-467E-8A9B-759504C53C34Q37627562-5D315C07-8D50-4A71-B496-0C26552CAD26Q37867043-79CFB4E7-88F4-42FC-9A57-7B0DF6A57E09Q37895291-4DE6982D-6184-4300-A55C-95F50DE8B99DQ38023747-C042C591-911B-4B07-8145-E84D24298546Q38027256-13FFDBFA-3C81-4AF9-A96D-BBC650E03229Q38067160-9317E1E5-515C-4155-A6DD-048B72082025Q38155649-1C335A09-0DDB-44CA-B435-DF6BAC165109Q38172848-A9E7EE38-9102-48BF-87C1-17ED60729A96Q38250071-E96F437E-D2DB-4831-A17D-5F0A40D00B7AQ38360350-27E1BD4A-F47A-4EE5-B8F7-6C9104132B1AQ38368427-7DE01898-0CD8-4802-9CC1-A59AF622A2AAQ38385150-71DE114E-80B9-4137-8770-6E6E84133804Q38540840-A00A0218-6FB3-4C14-B3A2-18EB6FC6DD2FQ38593774-726F43B1-2EE9-4AA5-93F8-91051A35061FQ38617229-D84F9B56-D1D2-4D92-9402-ED52785655DCQ38758857-FABD929C-9DB5-4100-BD06-09A5BA43C02EQ38767006-39ED3167-DBF7-4809-980B-4A050F51C191Q38841735-2C6030F6-7C8B-4CB1-8102-C1482849FE4FQ38850769-E8087A36-0283-4310-9B3D-CB218461B422Q38980447-0AD038A2-7B70-4D80-B148-B1C0C33A4C16Q39030703-D48F69A8-C44C-4F6E-BEDD-EF51C6627539Q39137073-899D87B6-9CAF-4B68-94A0-E1EAF2F723D8Q39199908-2F520619-0758-4E9C-9034-D63441B13440Q39379196-3D25FDF4-459C-4589-B054-7F49692DC62A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francesco Silvestris
@ast
Francesco Silvestris
@en
Francesco Silvestris
@es
Francesco Silvestris
@nl
Francesco Silvestris
@sl
type
label
Francesco Silvestris
@ast
Francesco Silvestris
@en
Francesco Silvestris
@es
Francesco Silvestris
@nl
Francesco Silvestris
@sl
prefLabel
Francesco Silvestris
@ast
Francesco Silvestris
@en
Francesco Silvestris
@es
Francesco Silvestris
@nl
Francesco Silvestris
@sl
P106
P1153
7006416186
P21
P31
P496
0000-0002-5555-2617